Polymarket

Polymarket Predicts Near-Certain 'No' for Embiid's 2025-26 MVP Hopes Amid Injury Woes

A Polymarket prediction market for the 2025-26 NBA MVP award shows overwhelming odds against Joel Embiid, with his 'Yes' outcome trading at a minuscule 0.0005. This reflects the market's strong belief that Embiid's season, plagued by injuries, has effectively ended his MVP candidacy.

Admin

— 3 min read

As the 2025-26 NBA regular season draws to a close, a Polymarket prediction market tracking Joel Embiid's chances of winning the Most Valuable Player (MVP) award has settled into a near-unanimous 'No' outcome. With 'Yes' trading at a mere 0.0005 and 'No' at 0.9995, the market's collective intelligence strongly indicates that the Philadelphia 76ers star will not secure the prestigious individual honor.

The market, which will resolve to 'No' immediately if Embiid is not announced as a finalist for the award, highlights the critical role of player availability and consistent performance in the MVP race. For Embiid, the 2025-26 season has unfortunately been defined by significant injury setbacks.

A Season Derailed by Injuries

Joel Embiid has been sidelined since early March with a right oblique strain, a recent addition to a season already marred by recurring knee and shin issues. This latest injury, which kept him out since March 1, has meant he remains absent from the court as of March 21, 2026. Reports from mid-March indicated that Embiid had missed nine consecutive games due to the oblique strain, further exacerbating concerns about his durability. His extensive injury history, which includes foot stress fractures, orbital fractures, and multiple meniscus tears, has consistently impacted his ability to maintain a full season's workload. By March 15, Embiid had reportedly missed as many career regular-season games (485) as he had played, a stark illustration of his persistent struggles with health.

The 65-Game Eligibility Hurdle

A pivotal factor in Embiid's diminished MVP prospects is the NBA's 65-game minimum rule for eligibility for most regular-season awards, including MVP, which took effect from the 2023-24 season. Players must appear in at least 65 games and play a minimum of 20 minutes in each to qualify, though some protections exist for season-ending injuries. Given Embiid's prolonged absence and the late stage of the regular season (which typically concludes in mid-April), it is highly improbable he will meet this critical threshold for the 2025-26 season. His expected games played would fall far short, automatically disqualifying him from consideration.

Current MVP Landscape and Market Implication

The current MVP discussion for the 2025-26 season is dominated by players who have maintained high levels of performance and availability. Early indicators and predictive models for the 2025-26 MVP race place Nikola Jokić, Shai Gilgeous-Alexander, and Luka Dončić as the leading candidates, showcasing dominant seasons with strong team records. These players are expected to meet the stringent games-played criteria and are delivering consistent, high-impact performances. Embiid's hypothetical season averages of 26.6 points, 7.5 rebounds, and 3.9 assists in 31.2 minutes per game, as reported by StatMuse for the 2025-26 season, while still strong, reflect a campaign curtailed by injury and are overshadowed by the robust statistics of current frontrunners.

Furthermore, at 32 years old (born March 16, 1994), Embiid's age also works against recent MVP trends, which have seen the award predominantly go to players in their late 20s. The average age for MVP winners has historically hovered around 27-28, with fewer players aged 30 or older receiving the honor in recent decades.

The Polymarket odds, therefore, are a clear reflection of these realities. With Embiid's significant injury history, his current sidelined status, and the unforgiving 65-game eligibility rule, the market has all but closed the door on his 2025-26 MVP aspirations long before the official announcement of finalists, which typically occurs in April.

Sources:

Market data fetched at 2026-03-23 12:18 UTC | Polymarket ID: 564174

This article is generated by AI for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment decisions. Data sourced from Polymarket and public web sources.

Read more